Capsul Desk

Cutting headcount to survive the next milestone creates exposures distinct from those of growth, and most boards underestimate them.

ASCO ended a week ago. The filing and the deal structure that deserve a closer look.

Bundibugyo had no vaccine, no treatment, no diagnostic for seventeen years. It took 900 cases to change the math.

Two qualify as first-in-class among 2032's ten biggest oncology bets. So why is big pharma paying nine figures for assets that haven't read out?

Page 1 of 1